Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

NCT06673069 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to terminate study early. Decision not based on safety concerns.

Conditions

Interventions

Sponsor

Ionis Pharmaceuticals, Inc.